Low-dose vs. standard-dose alteplase for acute ischemic stroke: a real-world single-center retrospective study.

Xin-Lei Mao, Si-Si He, Ya-Xi Zhang, Cai-Dan Lin, Xin-Xin Chen, Shi-Zheng Zhang, Li-Na Ge, Qing-Qing Zhuang

Abstract read

In one paragraph

Article in Frontiers in neurology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Xin-Lei MaoDepartment of Neurology, Wenzhou Central Hospital & Dingli Clinical Institute of Wenzhou Medical University, Wenzhou, Zhejiang, China.

Si-Si HeDepartment of Neurology, Wenzhou Central Hospital & Dingli Clinical Institute of Wenzhou Medical University, Wenzhou, Zhejiang, China.

Ya-Xi ZhangDepartment of Neurology, Wenzhou Central Hospital & Dingli Clinical Institute of Wenzhou Medical University, Wenzhou, Zhejiang, China.

Cai-Dan LinDepartment of Neurology, Wenzhou Central Hospital & Dingli Clinical Institute of Wenzhou Medical University, Wenzhou, Zhejiang, China.

Xin-Xin ChenDepartment of Neurology, Wenzhou Central Hospital & Dingli Clinical Institute of Wenzhou Medical University, Wenzhou, Zhejiang, China.

Shi-Zheng ZhangDepartment of Neurology, Wenzhou Central Hospital & Dingli Clinical Institute of Wenzhou Medical University, Wenzhou, Zhejiang, China.

Li-Na GeDepartment of Neurology, Wenzhou Central Hospital & Dingli Clinical Institute of Wenzhou Medical University, Wenzhou, Zhejiang, China.

Qing-Qing ZhuangDepartment of Neurology, Wenzhou Central Hospital & Dingli Clinical Institute of Wenzhou Medical University, Wenzhou, Zhejiang, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objectives: To investigate the real-world usage patterns and clinical outcomes of low-dose (0.6 mg/kg) versus standard-dose (0.9 mg/kg) intravenous alteplase in patients with acute ischemic stroke (AIS). Methods: This single-center retrospective study included 707 patients with AIS who received intravenous thrombolysis at Wenzhou Central Hospital from December 2016 to April 2023. Baseline characteristics, treatment selection, and clinical outcomes were analyzed. The primary outcomes were 90-day functional outcomes (mRS 0-1 and mRS 0-2) and the incidence of symptomatic intracranial hemorrhage (sICH). Results: Low-dose alteplase was more commonly used in older patients ( Conclusion: The study highlights the complexity of treatment decision-making for intravenous alteplase in AIS, with significant influences from both patient and physician factors. Low-dose alteplase demonstrated similar clinical outcomes to standard-dose alteplase in this real-world setting. Future research should focus on optimizing treatment decisions and improving guideline adherence to enhance patient outcomes.

Indexed as

acute ischemic strokealteplaselow-dosereal-world studystandard-dose

Identifiers

PMID41195015

DOI10.3389/fneur.2025.1651307

PMCPMC12583200

What OpenQuestion holds

Textmetadata

LicenceCC BY

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.